BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35982032)

  • 21. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
    Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
    J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [
    Patel CB; Beinat C; Xie Y; Chang E; Gambhir SS
    Neoplasia; 2021 Jan; 23(1):58-67. PubMed ID: 33221711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theory and application of TTFields in newly diagnosed glioblastoma.
    Yu A; Zeng J; Yu J; Cao S; Li A
    CNS Neurosci Ther; 2024 Mar; 30(3):e14563. PubMed ID: 38481068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.
    Wang J; Yan S; Chen X; Wang A; Han Z; Liu B; Shen H
    Technol Cancer Res Treat; 2022; 21():15330338211035270. PubMed ID: 35538679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
    Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
    IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor treating fields: narrative review of a promising treatment modality for cancer.
    Kutuk T; Atak E; La Rosa A; Kotecha R; Mehta MP; Chuong MD
    Chin Clin Oncol; 2023 Dec; 12(6):64. PubMed ID: 37953242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mechanisms of Action of Tumor Treating Fields.
    Moser JC; Salvador E; Deniz K; Swanson K; Tuszynski J; Carlson KW; Karanam NK; Patel CB; Story M; Lou E; Hagemann C
    Cancer Res; 2022 Oct; 82(20):3650-3658. PubMed ID: 35839284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
    Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
    Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).
    Shams S; Patel CB
    J Mol Cell Biol; 2022 Dec; 14(8):. PubMed ID: 35973687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields.
    Diamant G; Simchony Goldman H; Gasri Plotnitsky L; Roitman M; Shiloach T; Globerson-Levin A; Eshhar Z; Haim O; Pencovich N; Grossman R; Ram Z; Volovitz I
    J Immunol; 2021 Jul; 207(2):709-719. PubMed ID: 34215656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
    Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
    Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors.
    Benson L
    Semin Oncol Nurs; 2018 May; 34(2):137-150. PubMed ID: 29631935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.
    Lee YJ; Seo HW; Baek JH; Lim SH; Hwang SG; Kim EH
    Sci Rep; 2020 Jul; 10(1):12272. PubMed ID: 32704022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress and prospect in tumor treating fields treatment of glioblastoma.
    Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
    Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acceptance and compliance of TTFields treatment among high grade glioma patients.
    Onken J; Staub-Bartelt F; Vajkoczy P; Misch M
    J Neurooncol; 2018 Aug; 139(1):177-184. PubMed ID: 29644485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.
    Chen D; Le SB; Hutchinson TE; Calinescu AA; Sebastian M; Jin D; Liu T; Ghiaseddin A; Rahman M; Tran DD
    J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35199647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
    Dono A; Mitra S; Shah M; Takayasu T; Zhu JJ; Tandon N; Patel CB; Esquenazi Y; Ballester LY
    J Neurooncol; 2021 May; 153(1):153-160. PubMed ID: 33881725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.